Michael S Leapman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2743278/publications.pdf

Version: 2024-02-01

111 papers	1,183 citations	430442 18 h-index	454577 30 g-index
113 all docs	113 docs citations	113 times ranked	1792 citing authors

#	Article	IF	Citations
1	Evaluation of Online Telehealth Platforms for Treatment of Erectile Dysfunction. Reply.. Journal of Urology, 2022, 207, 247-248.	0.2	1
2	Pregnancy in physicians: A scoping review. American Journal of Surgery, 2022, 223, 36-46.	0.9	21
3	Distribution of Coronavirus Aid, Relief, and Economic Security (CARES) Act Provider Relief Fund Assistance to Urology Practices. Journal of Urology, 2022, 207, 7-8.	0.2	5
4	Characteristics of Online Crowdfunding Campaigns for Urological Cancers in the United States. Urology Practice, 2022, 9, 56-63.	0.2	3
5	Access to Colorectal Cancer Care for Medicaid-Insured Patients at Designated Cancer Facilities. Annals of Surgical Oncology, 2022, 29, 1518-1522.	0.7	5
6	Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology, 2022, 8, 41.	3.4	25
7	Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma. Journal of Geriatric Oncology, 2022, 13, 614-623.	0.5	2
8	Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. European Urology Open Science, 2022, 37, 113-119.	0.2	10
9	Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2022, 40, 300-300.	0.8	0
10	Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies.. Journal of Clinical Oncology, 2022, 40, 283-283.	0.8	0
11	Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer. JAMA Oncology, 2022, 8, 687.	3.4	20
12	Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice, 2022, 9, 140-149.	0.2	0
13	Access to Urological Care for Medicaid-Insured Patients at Urology Practices Acquired by Private Equity Firms. Urology, 2022, 164, 112-117.	0.5	9
14	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2022, 82, 82-96.	0.9	15
15	Acceptance of Simulated Adult Patients With Medicaid Insurance Seeking Care in a Cancer Hospital for a New Cancer Diagnosis. JAMA Network Open, 2022, 5, e2222214.	2.8	21
16	National trends in the management of patients with positive surgical margins at radical prostatectomy. World Journal of Urology, 2021, 39, 1141-1151.	1.2	0
17	When and How Should Active Surveillance for Prostate Cancer be De-Escalated?. European Urology Focus, 2021, 7, 297-300.	1.6	8
18	Outcomes of Serial Multiparametric Magnetic Resonance Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active Surveillance. European Urology Focus, 2021, 7, 47-54.	1.6	22

#	Article	IF	Citations
19	Contemporary Trends in Magnetic Resonance Imaging at the Time of Prostate Biopsy: Results from a Large Private Insurance Database. European Urology Focus, 2021, 7, 86-94.	1.6	28
20	Association Between Twitter Reception at a National Urology Conference and Future Publication Status. European Urology Focus, 2021, 7, 214-220.	1.6	12
21	Evaluation of Online Telehealth Platforms for Treatment of Erectile Dysfunction. Journal of Urology, 2021, 205, 330-332.	0.2	8
22	Doubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical Prostatectomy. Case Reports in Urology, 2021, 2021, 1-4.	0.1	0
23	Urology Residency Training in Medically Underserved Areas Through the Integration of a Federally Qualified Health Center Rotation. Urology, 2021, 149, 52-57.	0.5	3
24	Life Cycle Greenhouse Gas Emissions of Gastrointestinal Biopsies in a Surgical Pathology Laboratory. American Journal of Clinical Pathology, 2021, 156, 540-549.	0.4	43
25	Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. European Urology, 2021, 80, 549-563.	0.9	53
26	Accessibility of Telehealth services for cancer care at cancer hospital in the United States.. Journal of Clinical Oncology, 2021, 39, 6535-6535.	0.8	1
27	Mediators of racial disparity in the use of prostate MRI.. Journal of Clinical Oncology, 2021, 39, 6554-6554.	0.8	0
28	Access to cancer care for Medicaid patients at cancer hospitals in the United States.. Journal of Clinical Oncology, 2021, 39, 6548-6548.	0.8	2
29	Change in facility-level share of Medicaid patients with cancer following implementation of the affordable care act.. Journal of Clinical Oncology, 2021, 39, e18543-e18543.	0.8	0
30	Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of Urology, 2021, 205, 1559-1568.	0.2	2
31	A disease by any other name: Effects of cancer grading nomenclature on perception of prostate cancer risk. Cancer, 2021, 127, 3290-3293.	2.0	0
32	Access to Urologic Care at Urgent Care Centers. Urology, 2021, 156, 124-128.	0.5	2
33	When is a Seminoma not a Seminoma? The Incidence, Risk Factors and Management of Patients With Testicular Seminoma With Discordant Elevated Serum Alpha-fetoprotein. Urology, 2021, , .	0.5	0
34	The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 496.e17-496.e24.	0.8	5
35	Providerâ€•and patientâ€level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Cancer Medicine, 2021, 10, 6653-6665.	1.3	2
36	The Prognostic Association of Prostate MRI PI-RADSâ„¢ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of Urology, 2021, 206, 507-516.	0.2	22

#	Article	IF	Citations
37	Utility of PSA Density in Predicting Upgraded Gleason Score in Men on Active Surveillance With Negative MRI. Urology, 2021, 155, 96-100.	0.5	7
38	Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.. Journal of Clinical Oncology, 2021, 39, 116-116.	0.8	0
39	Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2021, 39, 87-87.	0.8	0
40	Incidence, risk factors, and outcome of Clostridioides difficile infection following urologicalÂsurgeries. World Journal of Urology, 2021, 39, 2995-3003.	1.2	2
41	Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer. JAMA Oncology, 2021, 7, 52.	3.4	12
42	Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer and Prostatic Diseases, 2021, 24, 414-422.	2.0	9
43	Cachexia and bladder cancer: clinical impact and management. Current Opinion in Supportive and Palliative Care, 2021, 15, 260-265.	0.5	4
44	Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open, 2021, 4, e2128646.	2.8	8
45	AUTHOR REPLY. Urology, 2021, 157, 196.	0.5	0
46	Outcomes for urologic oncology procedures: are there differences between academic and community hospitals?. World Journal of Urology, 2020, 38, 1187-1193.	1.2	5
47	Effect of Diaphragmatic Breathing on Procedural Anxiety During Transrectal Prostate Biopsy. Urology, 2020, 137, 26-32.	0.5	10
48	Trends in prostatectomy utilization: Increasing upfront prostatectomy and postprostatectomy radiotherapy for highâ€risk prostate cancer. Cancer Medicine, 2020, 9, 8754-8764.	1.3	12
49	The Green Print: Advancement of Environmental Sustainability in Healthcare. Resources, Conservation and Recycling, 2020, 161, 104882.	5.3	121
50	Radiation Dose to the Rectum With Definitive Radiation Therapy and Hydrogel Spacer Versus Postprostatectomy Radiation Therapy. Advances in Radiation Oncology, 2020, 5, 1225-1231.	0.6	0
51	Evaluation of Cancer Care After Medicaid Expansion Under the Affordable Care Act. JAMA Network Open, 2020, 3, e2017544.	2.8	3
52	Online Crowdfunding Response to Coronavirus Disease 2019. Journal of General Internal Medicine, 2020, 35, 2482-2484.	1.3	25
53	Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Nonâ€“Small Cell Lung Cancer. JAMA Network Open, 2020, 3, e207205.	2.8	19
54	Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma. Current Oncology Reports, 2020, 22, 35.	1.8	3

#	Article	IF	Citations
55	Association of prescription opioids and incident cardiovascular risk factors among post-9/11 Veterans. Preventive Medicine, 2020, 134, 106036.	1.6	2
56	Sight and switch off: Nerve density visualization for interventions targeting nerves in prostate cancer. Science Advances, 2020, 6, eaax6040.	4.7	28
57	How should radiologists incorporate non-imaging prostate cancer biomarkers into daily practice?. Abdominal Radiology, 2020, 45, 4031-4039.	1.0	6
58	Chasing the Pack: Association between Urology Hospital Rankings and Surgical Outcome. Journal of Urology, 2020, 203, 890-891.	0.2	1
59	Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer.. Journal of Clinical Oncology, 2020, 38, e19308-e19308.	0.8	0
60	Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity.. Journal of Clinical Oncology, 2020, 38, e17609-e17609.	0.8	0
61	Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.. Journal of Clinical Oncology, 2020, 38, 748-748.	0.8	0
62	Editorial Comment. Journal of Urology, 2020, 203, 705-705.	0.2	0
63	Determinants of Active Surveillance in Patients With Small Renal Masses. Urology, 2019, 123, 167-173.	0.5	16
64	Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. Urology, 2019, 124, 98-106.	0.5	9
65	Association Between Tumor Multifocality on Multi-parametric MRI and Detection of Clinically-Significant Prostate Cancer in Lesions with Prostate Imaging Reporting and Data System (PI-RADS) Score 4. Urology, 2019, 134, 173-180.	0.5	3
66	Knowledge and Practices of Physicians and Nurses Related to Urine Cultures in Catheterized Patients: An Assessment of Adherence to IDSA Guidelines. Open Forum Infectious Diseases, 2019, 6, .	0.4	15
67	Robot-Assisted Excision of Congenital Mega-Seminal Vesicle Associated with Zinner's Syndrome. Journal of Endourology Case Reports, 2019, 5, 4-6.	0.3	8
68	Role of Core Number and Location in Targeted Magnetic Resonance Imaging-Ultrasound Fusion Prostate Biopsy. European Urology, 2019, 76, 14-17.	0.9	64
69	AUTHOR REPLY. Urology, 2019, 124, 106.	0.5	0
70	National trends and economic impact of surgical treatment for benign kidney tumors. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 183.e9-183.e15.	0.8	6
71	Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer. Journal of Urology, 2019, 202, 696-701.	0.2	16
72	Clinical risk-based associations of lymph node dissection and detection of metastasis among men treated with radical prostatectomy.. Journal of Clinical Oncology, 2019, 37, 284-284.	0.8	0

#	Article	IF	Citations
73	National trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder.. Journal of Clinical Oncology, 2019, 37, 477-477.	0.8	0
74	The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance?. Journal of Clinical Oncology, 2019, 37, 485-485.	0.8	0
75	Associations of rurality and disease outcomes in urologic malignancies.. Journal of Clinical Oncology, 2019, 37, 661-661.	0.8	3
76	Urologic malignancies: A comparison of outcomes after index surgery between academic and community hospitals.. Journal of Clinical Oncology, 2019, 37, 489-489.	0.8	0
77	Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, 9059-9059.	0.8	0
78	Genetic testing for hereditary prostate cancer: Current status and limitations. Cancer, 2018, 124, 3105-3117.	2.0	72
79	Survival outcomes for patients with localised upper tract urothelial carcinoma managed with nonâ€definitive treatment. BJU International, 2018, 121, 124-129.	1.3	6
80	2119. Reducing Catheter-Associated Urinary Tract Infections Using an Evidence-Based Urine Culture Algorithm at an Academic Medical Center. Open Forum Infectious Diseases, 2018, 5, S622-S623.	0.4	1
81	Variation in National Opioid Prescribing Patterns Following Surgery for Kidney Stones. Pain Medicine, 2018, 19, S12-S18.	0.9	20
82	Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. European Urology, 2018, 74, 668-675.	0.9	34
83	Editorial Comment. Journal of Urology, 2018, 200, 572-572.	0.2	0
84	National trends in the management of patients with positive surgical margins at the time of radical prostatectomy.. Journal of Clinical Oncology, 2018, 36, 111-111.	0.8	2
85	Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy.. Journal of Clinical Oncology, 2018, 36, 118-118.	0.8	2
86	How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy?. Journal of Clinical Oncology, 2018, 36, 134-134.	0.8	2
87	Heterogeneity in early oncologic outcomes among men with NCCN intermediate-risk prostate cancer treated with radical prostatectomy.. Journal of Clinical Oncology, 2018, 36, 144-144.	0.8	0
88	Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI?. Journal of Clinical Oncology, 2018, 36, 149-149.	0.8	0
89	Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance.. Journal of Clinical Oncology, 2018, 36, 114-114.	0.8	0
90	National determinants of active surveillance among patients with clinical stage 1A kidney tumors.. Journal of Clinical Oncology, 2018, 36, 694-694.	0.8	0

#	Article	IF	Citations
91	Risk Stratification of Newly Diagnosed Prostate Cancer with GenomicÂPlatforms. Urology Practice, 2017, 4, 322-328.	0.2	0
92	Up and Away: Five Decades of Urologic Investigation in Microgravity. Urology, 2017, 106, 18-25.	0.5	4
93	Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. European Urology, 2017, 71, 750-759.	0.9	40
94	Separating Opioid Fact and Fiction in Urology. Journal of Urology, 2017, 198, 990-992.	0.2	1
95	Reply by the Authors. Urology, 2017, 110, 266.	0.5	0
96	What is the best way not to treat prostate cancer?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 42-50.	0.8	13
97	Validity of the Cancer of the Prostate Risk Assessment Score Derived From Targeted Biopsy: Modeling Evidence From Ultrasound Lesion-Directed Biopsy. Clinical Genitourinary Cancer, 2017, 15, 93-99.	0.9	1
98	A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy. Journal of Urology, 2017, 197, 369-375.	0.2	19
99	Impact of the integration of proton magnetic resonance imaging spectroscopy to PI-RADS 2 for prediction of high grade and high stage prostate cancer. Radiologia Brasileira, 2017, 50, 299-307.	0.3	11
100	Active Surveillance in Younger Men With Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 1898-1904.	0.8	46
101	Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). PLoS ONE, 2017, 12, e0185535.	1.1	22
102	Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. Journal of Urology, 2016, 196, 1408-1414.	0.2	43
103	The impact of timing of salvage hormonal therapy on survival after brachytherapy for prostate cancer. Brachytherapy, 2016, 15, 730-735.	0.2	2
104	Clinical Utility of Biomarkers in Localized Prostate Cancer. Current Oncology Reports, 2016, 18, 30.	1.8	13
105	Serial Anatomical Prostate Ultrasound during Prostate Cancer Active Surveillance. Journal of Urology, 2016, 196, 727-733.	0.2	4
106	Editorial Comment. Urology, 2016, 93, 84-85.	0.5	0
107	New Genetic Markers for Prostate Cancer. Urologic Clinics of North America, 2016, 43, 7-15.	0.8	12
108	Patterns of Local Failure following Radiation Therapy for Prostate Cancer. Journal of Urology, 2015, 194, 977-982.	0.2	39

#	Article	IF	Citations
109	Current Use of Imaging after Primary Treatment of Prostate Cancer. Journal of Urology, 2015, 194, 98-104.	0.2	4
110	Fermented Soy Drink (Q-CANÂ® PLUS) Induces Apoptosis and Reduces Viability of Cancer Cells. Nutrition and Cancer, 0, , 1-10.	0.9	1
111	COVID-19 Misinformation: Social Network Crowd-Funding for Alternative COVID-19 Treatments and Anti-Vaccine Mandates (Preprint). Journal of Medical Internet Research, 0, , .	2.1	2